- Home
- BILI vs PODD Comparison
BILI vs PODD Comparison
Compare BILI & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BILI | PODD |
|---|---|---|
| Founded | 2009 | 2000 |
| Country | China | United States |
| Employees | 8088 | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 10.3B |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | BILI | PODD |
|---|---|---|
| Price | $18.32 | $163.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 21 |
| Target Price | $31.13 | ★ $341.48 |
| AVG Volume (30 Days) | ★ 2.2M | 1.4M |
| Earning Date | 05-19-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.30 |
| Revenue | N/A | ★ $2,708,100,000.00 |
| Revenue This Year | $11.77 | $24.55 |
| Revenue Next Year | $9.59 | $19.18 |
| P/E Ratio | ★ $122.37 | $128.75 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $15.79 | $138.79 |
| 52 Week High | $36.40 | $354.88 |
Technical Indicators
Market Signals| Indicator | BILI | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 53.29 | 55.59 |
| Support Level | $17.12 | $141.67 |
| Resistance Level | $18.91 | $164.59 |
| Average True Range (ATR) | 0.45 | 6.04 |
| MACD | 0.19 | 0.83 |
| Stochastic Oscillator | 63.24 | 62.33 |
Price Performance
Historical ComparisonAbout BILI Bilibili Inc.
Bilibili is a Chinese online entertainment platform best known for its YouTube-like video-sharing service. Founded in 2009, it initially focused on long-form content centered around anime, comics, and gaming, or ACG, catering primarily to Generation Z users. Over time, the platform has expanded its content ecosystem to cover a broader range of interests, successfully attracting a more diverse audience beyond its original Gen Z base.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.